Search

Your search keyword '"Neuzillet Y"' showing total 7 results
Start Over Author "Neuzillet Y" Language undetermined
7 results on '"Neuzillet Y"'

3. De novo kidney graft tumors: results from a multicentric retrospective national study

Author

Tillou, X., Doerfler, A., Collon, S., Kleinclauss, F., Patard, J.-J., Badet, L., Barrou, B., Audet, M., Bensadoun, H., Berthoux, E., Bigot, P., Boutin, J.-M., Bouzguenda, Y., Chambade, D., Codas, R., Dantal, J., Deturmeny, J., Devonec, M., Dugardin, F., Ferrière, J.-M., Erauso, A., Feuillu, B., Gigante, M., Guy, L., Karam, G., Lebret, T., Neuzillet, Y., Legendre, C., Perez, T., Rerolle, Jean-Philippe, Salomon, L., Sallusto, F., Sénéchal, C., Terrier, N., Thuret, R., Verhoest, G., Petit, J., Renseigné, Non, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Department of Civil Engineering [Lebanese American University] (CE/SOE/LAU), School of Engineering [Lebanese American University] (SOE/LAU), Lebanese American University (LAU)-Lebanese American University (LAU), Domaines Océaniques (LDO), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Observatoire des Sciences de l'Univers-Institut d'écologie et environnement-Centre National de la Recherche Scientifique (CNRS), Department of Environmental Science [Philippines], Ateneo de Manila University, Pharmacologie des Immunosuppresseurs et de la Transplantation (PIST), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, CHU Toulouse [Toulouse], Clinique d'urologie, and CHU Grenoble

Subjects
Male, MESH: Carcinoma, Papillary, medicine.medical_treatment, 030232 urology & nephrology, MESH: Kidney Transplantation, 0302 clinical medicine, MESH: Aged, 80 and over, Immunology and Allergy, Pharmacology (medical), MESH: Incidence, Kidney transplantation, MESH: Aged, Aged, 80 and over, Kidney, MESH: Middle Aged, Incidence, MESH: Carcinoma, Renal Cell, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Middle Aged, Prognosis, Nephrectomy, Kidney Neoplasms, 3. Good health, Survival Rate, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, France, Adult, medicine.medical_specialty, MESH: Survival Rate, Adolescent, MESH: Prognosis, 03 medical and health sciences, Young Adult, medicine, Carcinoma, Humans, Survival rate, Carcinoma, Renal Cell, Dialysis, Aged, Retrospective Studies, MESH: Adolescent, Transplantation, MESH: Humans, business.industry, Retrospective cohort study, MESH: Adult, MESH: Retrospective Studies, medicine.disease, Kidney Transplantation, MESH: Male, Carcinoma, Papillary, Surgery, MESH: France, MESH: Kidney Neoplasms, business, MESH: Female
Abstract

International audience; De novo tumors in renal allografts are rare and their prevalence is underestimated. We therefore analyzed renal cell carcinomas arising in renal allografts through a retrospective French renal transplant cohort. We performed a retrospective, multicentric survey by sending questionnaires to all French kidney transplantation centers. All graft tumors diagnosed after transplantation were considered as de novo tumors. Thirty-two centers participated in this study. Seventy-nine tumors were identified among 41 806 recipients (Incidence 0.19%). Patients were 54 men and 25 women with a mean age of 47 years old at the time of diagnosis. Mean tumor size was 27.8 mm. Seventy-four (93.6%), 53 (67%) and 44 tumors (55.6%) were organ confined (T1-2), low grade (G1-2) and papillary carcinomas, respectively. Four patients died of renal cell carcinomas (5%). The mean time lapse between transplantation and RCC diagnosis was 131.7 months. Thirty-five patients underwent conservative surgery by partial nephrectomy (n = 35, 44.3%) or radiofrequency (n = 5; 6.3%). The estimated 5 years cancer specific survival rate was 94%. Most of these tumors were small and incidental. Most tumors were papillary carcinoma, low stage and low grade carcinomas. Conservative treatment has been preferred each time it was feasible in order to avoid a return to dialysis.

Published
2012
Full Text
View/download PDF

6. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

Author

Marion Vandromme, Jean Philippe Spano, Olivier Cussenot, Chloé Rideau, Carole Corsini, Isabelle Treilleux, Michèle Vintraud, Ignace Vergote, Yves-Jean Bignon, Kevin S. Hughes, Bernard Baertschi, Eitan Friedman, Daniel Zarca, Marie Duboys de Labarre, Pascal Pujol, Jean Marc Rey, Joseph Gligorov, Ettore D. Capoluongo, Clarisse Duriez, Marion Imbert-Bouteille, Yann Neuzillet, Jean-Louis Mandel, Isabelle Ray-Coquard, Laurence Gladieff, Jose E. Alés Martínez, Frédérique Penault-Llorca, Karim Fizazi, Pierre Jean Lamy, Julie A. Vendrell, Pascal Hammel, Thibault De La Motte Rouge, Jesus Garcia Foncillas, Diether Lambrechts, Tatiana Kogut-Kubiak, Karen Baudry, William Jacot, William D. Foulkes, Frédéric Thomas, Sophie Nambot, Massimo Barberis, Michèle Anahory, Matti Aapro, Xavier Rebillard, Josep M. Piulats, Florence Duchamp, Steven A. Narod, Sylviane Olschwang, Banu Arun, Marc Bollet, Philp Beer, Clare Turnbull, Helen Hanson, Nicola Normanno, Virginie Galibert, Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre de Recherche pour les Pathologies Prostatiques [Paris] (CeRePP), Sorbonne Université (SU), Institut Universitaire de Cancérologie [Sorbonne Université] (IUC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CRLCC Eugène Marquis (CRLCC), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Gustave Roussy (IGR), Oncologie génito-urinaire, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut du Cancer de Montpellier (ICM), Institut médical d'anayse génomique (IMAGENOME), Labosud, Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Centre de Recherches Ecologiques et Evolutives sur le Cancer (MIVEGEC-CREEC), Processus Écologiques et Évolutifs au sein des Communautés (PEEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Centre Léon Bérard [Lyon], Harvard Medical School [Boston] (HMS), Hospital Nuestra Señora de Sonsoles, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Clinique Hartmann [Neuilly-sur-Seine], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Oncologie gynécologique, Institut Claudius Regaud, AP-HP Hôpital Tenon [Paris], Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP]-Université de Paris (UP), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Massachusetts General Hospital [Boston], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Pujol, P., Barberis, M., Beer, P., Friedman, E., Piulats, J. M., Capoluongo, E. D., Garcia Foncillas, J., Ray-Coquard, I., Penault-Llorca, F., Foulkes, W. D., Turnbull, C., Hanson, H., Narod, S., Arun, B. K., Aapro, M. S., Mandel, J. -L., Normanno, N., Lambrechts, D., Vergote, I., Anahory, M., Baertschi, B., Baudry, K., Bignon, Y. -J., Bollet, M., Corsini, C., Cussenot, O., De la Motte Rouge, T., Duboys de Labarre, M., Duchamp, F., Duriez, C., Fizazi, K., Galibert, V., Gladieff, L., Gligorov, J., Hammel, P., Imbert-Bouteille, M., Jacot, W., Kogut-Kubiak, T., Lamy, P. -J., Nambot, S., Neuzillet, Y., Olschwang, S., Rebillard, X., Rey, J. -M., Rideau, C., Spano, J. -P., Thomas, F., Treilleux, I., Vandromme, M., Vendrell, J., Vintraud, M., Zarca, D., Hughes, K. S., Ales Martinez, J. E., Institut Universitaire de Cancérologie [Paris] (IUC), Service d'urologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-CRLCC Eugène Marquis (CRLCC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Service d'Oncologie médicale [CHU Pitié-Salpêtrière], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, endocrine system diseases, Genetic counseling, Advanced breast, [SDV]Life Sciences [q-bio], BRCA1 and BRCA2 testing, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Guideline, Guidelines, BRCA-related cancer, Càncer de mama, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, medicine, Humans, Genetic Testing, Intensive care medicine, skin and connective tissue diseases, PARP inhibitors, Germ-Line Mutation, Genetic testing, BRCA2 Protein, Ovarian Neoplasms, Adjuvant treatment of cancer, medicine.diagnostic_test, business.industry, BRCA1 Protein, Cancer, medicine.disease, Metastatic breast cancer, 3. Good health, Clinical Practice, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, PARP inhibitor, Practice Guidelines as Topic, Female, Risk assessment, business, Tractament adjuvant del càncer
Abstract

BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now overlap with both preventive and therapeutic management, updated and comprehensive practice guidelines for BRCA genotyping are needed. The integrative recommendations for BRCA testing presented here aim to (1) identify individuals who may benefit from genetic counselling and risk-reducing strategies; (2) update germline and tumour-testing indications for PARPi-approved therapies; (3) provide testing recommendations for personalised management of early and metastatic breast cancer; and (4) address the issues of rapid process and tumour analysis. An international group of experts, including geneticists, medical and surgical oncologists, pathologists, ethicists and patient representatives, was commissioned by the French Society of Predictive and Personalised Medicine (SFMPP). The group followed a methodology based on specific formal guidelines development, including (1) evaluating the likelihood of BRCAm from a combined systematic review of the literature, risk assessment models and expert quotations, and (2) therapeutic values of BRCAm status for PARPi therapy in BRCA-related cancer and for management of early and advanced breast cancer. These international guidelines may help clinicians comprehensively update and standardise BRCA testing practices. ispartof: EUROPEAN JOURNAL OF CANCER vol:146 pages:30-47 ispartof: location:England status: published

Published
2021
Full Text
View/download PDF

7. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients

Author

Laura S. Mertens, Francesco Claps, Roman Mayr, Peter J. Bostrom, Shahrokh F. Shariat, Ellen C. Zwarthoff, Joost L. Boormans, Cheno Abas, Geert J.L.H. van Leenders, Stefanie Götz, Katrin Hippe, Simone Bertz, Yann Neuzillet, Joyce Sanders, Annegien Broeks, Dennis Peters, Michiel S. van der Heijden, Michael A.S. Jewett, Robert Stöhr, Alexandre R. Zlotta, Markus Eckstein, Yanish Soorojebally, Deric K.E. van der Schoot, Bernd Wullich, Maximilian Burger, Wolfgang Otto, François Radvanyi, Nanour Sirab, Damien Pouessel, Theo H. van der Kwast, Arndt Hartmann, Yair Lotan, Yves Allory, Tahlita C.M. Zuiverloon, Bas W.G. van Rhijn, Mertens, L. S., Claps, F., Mayr, R., Bostrom, P. J., Shariat, S. F., Zwarthoff, E. C., Boormans, J. L., Abas, C., van Leenders, G. J. L. H., Gotz, S., Hippe, K., Bertz, S., Neuzillet, Y., Sanders, J., Broeks, A., Peters, D., van der Heijden, M. S., Jewett, M. A. S., Stohr, R., Zlotta, A. R., Eckstein, M., Soorojebally, Y., van der Schoot, D. K. E., Wullich, B., Burger, M., Otto, W., Radvanyi, F., Sirab, N., Pouessel, D., van der Kwast, T. H., Hartmann, A., Lotan, Y., Allory, Y., Zuiverloon, T. C. M., van Rhijn, B. W. G., Pathology, and Urology

Subjects
Male, p53, Bladder, Urology, Prognosis, Cystectomy, Immunohistochemistry, Cancer, FGFR3, Ki-67, Mutation, Urothelial carcinoma, Ki-67 Antigen, Urinary Bladder Neoplasms, SDG 3 - Good Health and Well-being, Oncology, Humans, Receptor, Fibroblast Growth Factor, Type 3, Female, Tumor Suppressor Protein p53, Retrospective Studies
Abstract

Objectives: To determine the association between the FGFR3 mutation status and immuno-histochemistry (IHC) markers (p53 and Ki-67) in invasive bladder cancer (BC), and to analyze their prognostic value in a multicenter, multi-laboratory radical cystectomy (RC) cohort. Patients and methods: We included 1058 cN0M0, chemotherapy-naive BC patients who underwent RC with pelvic lymph-node dissection at 8 hospitals. The specimens were reviewed by uro-pathologists. Mutations in the FGFR3 gene were examined using PCR-SNaPshot; p53 and Ki-67 expression were determined by standard IHC. FGFR3 mutation status as well as p53 (cut-off>10%) and Ki-67 (cut-off>20%) expression were correlated to clinicopathological parameters and disease specific survival (DSS). Results: pT-stage was

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results